-
Novel program for early-onset morbid obesity licensed to Pfizer
MONTREAL | The Institute for Research in Immunology and Cancer - Commercialization of Research and its host institution, the Université de Montréal, have licensed a novel early-onset morbid obesity pre-clinical program to Pfizer. The program was developed at the Institute for Research in Immunology and Cancer.